Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)

Recruiting

• Conditions: Atrial Fibrillation

• Registration Number: NCT02786095
• Lead Sponsor: Yonsei University

Brief Summary

This study is prospective Cohort study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is all patients with atrial fibrillation who visit hospital. The purpose is to analyze complication, composite outcome (all cause mortality, hospitalization, the incidence of stroke, heart failure and cardiovascular event (MACE)) according to the 1) the use of anti-arrhythmic drugs (AADs), 2) use of medication for rate control (beta blocker, calcium channel blocker and digoxin) and 3) use of anticoagulation agents (warfarin, coumadin, an NOAC)

Detailed Description

Not available

Study Timeline

• Study Start: 2016-05-01
• Study First Submitted: 2016-05-25
• Study First Submitted QC: 2016-05-27
• Study First Posted: 2016-05-30
• Status Verified: 2018-06
• Last Update Submitted: 2018-06-19
• Last Update Posted: 2018-06-20
• Primary Completion: 2024-10
• Study Completion: 2024-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20000

Inclusion Criteria

• patients with atrial fibrillation
• patients with age more than 19
• patients who agree with study inclusion

Read More

Exclusion Criteria

• patients who do not agree with study inclusion
• patients with age less than 19
• Pregnancy, Breastfeeding

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
number of hospitalization by heart failure	3 years
number of recurrent stroke	3 years
number of cardiovascular events	3 years
all cause mortality	3 years

Trial Locations

Locations (1)

Division of Cardiology, Yonsei University Health System, Yonsei University College of Medicine; 🇰🇷 Seoul, Korea, Republic of